{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:54:58Z","timestamp":1740167698119,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40119-024-00380-7","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T06:02:00Z","timestamp":1722664920000},"page":"603-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Four-Factor Prothrombin Complex Concentrate in Special Populations with INR Below 2: A Post-Marketing Surveillance Study"],"prefix":"10.1007","volume":"13","author":[{"given":"Masahiro","family":"Yasaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Kiyonaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2767-5060","authenticated-orcid":false,"given":"Naoki","family":"Terasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"380_CR1","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/ijs.12452","volume":"10","author":"K Toyoda","year":"2015","unstructured":"Toyoda K, Arihiro S, Todo K, et al. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836\u201342.","journal-title":"Int J Stroke"},{"key":"380_CR2","doi-asserted-by":"crossref","unstructured":"Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010;170:1926\u201333.","DOI":"10.1001\/archinternmed.2010.407"},{"key":"380_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"380_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"380_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"380_CR6","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"380_CR7","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:257S\u2013298S.","journal-title":"Chest"},{"key":"380_CR8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/bmj.325.7368.828","volume":"325","author":"DA Fitzmaurice","year":"2002","unstructured":"Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002;325:828\u201331.","journal-title":"BMJ"},{"key":"380_CR9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/europace\/eur126","volume":"13","author":"GY Lip","year":"2011","unstructured":"Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723\u201346.","journal-title":"Europace"},{"key":"380_CR10","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.amjmed.2006.07.034","volume":"120","author":"MC Fang","year":"2007","unstructured":"Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700\u20135.","journal-title":"Am J Med"},{"key":"380_CR11","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/STROKEAHA.111.630731","volume":"43","author":"MC Fang","year":"2012","unstructured":"Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43:1795\u20139.","journal-title":"Stroke"},{"key":"380_CR12","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","volume":"86","author":"K Ono","year":"2022","unstructured":"Ono K, Iwasaki Y, Akao M, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. Circ J. 2022;86:1790\u2013924.","journal-title":"Circ J"},{"key":"380_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","volume":"9","author":"A Chen","year":"2020","unstructured":"Chen A, Stecker E, Warden BA, et al. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020;9:e017559. https:\/\/doi.org\/10.1161\/JAHA.120.017559.","journal-title":"J Am Heart Assoc"},{"key":"380_CR14","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S\u2013e88S.","journal-title":"Chest"},{"key":"380_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/j.1537-2995.2008.02080.x","volume":"49","author":"L Holland","year":"2009","unstructured":"Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49:1171\u20137.","journal-title":"Transfusion"},{"key":"380_CR16","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","volume":"53","author":"SM Greenberg","year":"2022","unstructured":"Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2022;53:e282\u2013361.","journal-title":"Stroke"},{"key":"380_CR17","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1111\/trf.13191","volume":"55","author":"MA Refaai","year":"2015","unstructured":"Refaai MA, Goldstein JN, Lee ML, et al. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin\u00a0K antagonist reversal. Transfusion. 2015;55:2722\u20139.","journal-title":"Transfusion"},{"key":"380_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1538-7836.2008.02904.x","volume":"6","author":"I Pabinger","year":"2008","unstructured":"Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P\/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622\u201331.","journal-title":"J Thromb Haemost"},{"key":"380_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","volume":"128","author":"R Sarode","year":"2013","unstructured":"Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin\u00a0K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase\u00a0IIIb study. Circulation. 2013;128:1234\u201343.","journal-title":"Circulation"},{"key":"380_CR20","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(14)61685-8","volume":"385","author":"JN Goldstein","year":"2015","unstructured":"Goldstein JN, Refaai MA, Milling TJ Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin\u00a0K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase\u00a03b, open-label, non-inferiority, randomised trial. Lancet. 2015;385:2077\u201387.","journal-title":"Lancet"},{"key":"380_CR21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40119-024-00357-6","volume":"13","author":"M Yasaka","year":"2024","unstructured":"Yasaka M, Suzuki M, Kushimoto S, et al. Real-world safety and effectiveness of a 4-factor prothrombin complex concentrate in Japanese patients experiencing major bleeding: a post-marketing surveillance study. Cardiol Ther. 2024;13:221\u201332.","journal-title":"Cardiol Ther"},{"key":"380_CR22","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1253\/circj.CJ-13-0290","volume":"77","author":"H Inoue","year":"2013","unstructured":"Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. Circ J. 2013;77:2264\u201370.","journal-title":"Circ J"},{"key":"380_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jjcc.2014.07.013","volume":"65","author":"T Yamashita","year":"2015","unstructured":"Yamashita T, Inoue H, Okumura K, et al. Warfarin anticoagulation intensity in Japanese nonvalvular atrial fibrillation patients: a J-RHYTHM Registry analysis. J Cardiol. 2015;65:175\u20137.","journal-title":"J Cardiol"},{"key":"380_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1253\/circj.CJ-14-1057","volume":"79","author":"E Kodani","year":"2015","unstructured":"Kodani E, Atarashi H, Inoue H, et al. Target intensity of anticoagulation with warfarin in Japanese patients with valvular atrial fibrillation: subanalysis of the J-RHYTHM Registry. Circ J. 2015;79:325\u201330.","journal-title":"Circ J"},{"key":"380_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12185-017-2311-4","volume":"106","author":"S Kushimoto","year":"2017","unstructured":"Kushimoto S, Fukuoka T, Kimura A, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin\u00a0K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase\u00a03b study. Int J Hematol. 2017;106:777\u201386.","journal-title":"Int J Hematol"},{"key":"380_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, et al. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50:309\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"380_CR27","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00003495-200969060-00001","volume":"69","author":"K Toyoda","year":"2009","unstructured":"Toyoda K. Pharmacotherapy for the secondary prevention of stroke. Drugs. 2009;69:633\u201347.","journal-title":"Drugs"},{"key":"380_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1253\/circj.71.761","volume":"7","author":"S Suzuki","year":"2007","unstructured":"Suzuki S, Yamashita T, Kato T, et al. Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J. 2007;7:761\u20135.","journal-title":"Circ J"},{"key":"380_CR29","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1182\/bloodadvances.2020002267","volume":"4","author":"R Sarode","year":"2020","unstructured":"Sarode R, Fukutake K, Yasaka M, et al. Pharmacometric modeling to explore 4F-PCC dosing strategies for VKA reversal in patients with INR below 2. Blood Adv. 2020;4:4208\u201316.","journal-title":"Blood Adv"},{"key":"380_CR30","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12028-017-0422-7","volume":"27","author":"WR Zemrak","year":"2017","unstructured":"Zemrak WR, Smith KE, Rolfe SS, et al. Low-dose prothrombin complex concentrate for warfarin-associated intracranial hemorrhage with INR less than 2.0. Neurocrit Care. 2017;27:334\u201340.","journal-title":"Neurocrit Care"},{"key":"380_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s12028-016-0271-9","volume":"25","author":"RM Rivosecchi","year":"2016","unstructured":"Rivosecchi RM, Durkin J, Okonkwo DO, et al. Safety and efficacy of warfarin reversal with four-factor prothrombin complex concentratefor subtherapeutic INR in intracerebral hemorrhage. Neurocrit Care. 2016;25:359\u201364.","journal-title":"Neurocrit Care"},{"key":"380_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","volume":"24","author":"JA Frontera","year":"2016","unstructured":"Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24:6\u201346.","journal-title":"Neurocrit Care"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-024-00380-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-024-00380-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T15:28:43Z","timestamp":1724081323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-024-00380-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s40119-024-00380-7","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"type":"print","value":"2193-8261"},{"type":"electronic","value":"2193-6544"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Fumihiko Shimizu, Ayako Kiyonaga, Yuki Niwa and Naoki Terasaka are full-time employees of CSL Behring. Masahiro Yasaka has received lecture, advisory, and travel fees from AstraZeneca, Bristol-Myers Squibb, Nippon Boehringer Ingelheim, Bayer, Daiichi Sankyo, and CSL Behring, as well as scholarship funds or nonrestricted grants from Nippon Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was carried out in compliance with the Declaration of Helsinki (1964 and its subsequent amendments). It also adhered to the principles outlined in the Japanese Good Postmarketing Study Practice (GPSP) regulations. The protocol was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) and by the ethics committees. All participating patients provided comprehensive, written informed consent. All Japanese sites that administered 4F-PCC post-approval participated in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}